Last reviewed · How we verify
Dacomitinib (PF-00299804)
Dacomitinib is a pan-HER tyrosine kinase inhibitor that irreversibly blocks EGFR, HER2, and HER4 signaling to inhibit tumor cell growth.
Dacomitinib is a pan-HER tyrosine kinase inhibitor that irreversibly blocks EGFR, HER2, and HER4 signaling to inhibit tumor cell growth. Used for Non-small cell lung cancer (NSCLC) with EGFR mutations, First-line treatment of metastatic NSCLC with EGFR-activating mutations.
At a glance
| Generic name | Dacomitinib (PF-00299804) |
|---|---|
| Also known as | Dacomitinib |
| Sponsor | Pfizer |
| Drug class | Pan-HER tyrosine kinase inhibitor |
| Target | EGFR, HER2, HER4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Dacomitinib covalently binds to and inhibits multiple members of the human epidermal growth factor receptor (HER) family, particularly EGFR, HER2, and HER4. By blocking these receptor tyrosine kinases, it prevents downstream signaling pathways that drive cell proliferation and survival in HER-dependent cancers. This pan-HER inhibition provides broader coverage than first-generation EGFR inhibitors.
Approved indications
- Non-small cell lung cancer (NSCLC) with EGFR mutations
- First-line treatment of metastatic NSCLC with EGFR-activating mutations
Common side effects
- Diarrhea
- Rash/dermatitis
- Nausea
- Vomiting
- Fatigue
- Stomatitis
- Decreased appetite
Key clinical trials
- Korea Post Marketing Surveillance (PMS) Study of Vizimpro
- Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer (PHASE1)
- Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer
- Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (PHASE2)
- A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.
- Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC (PHASE1, PHASE2)
- Phase 2 Study of Dacomitinib in NSCLC (PHASE2)
- Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dacomitinib (PF-00299804) CI brief — competitive landscape report
- Dacomitinib (PF-00299804) updates RSS · CI watch RSS
- Pfizer portfolio CI